Onxeo’s shares transferred to Compartment B on Euronext Paris
Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces that its shares will be transferred from Compartment C to Compartment B of the NYSE Euronext Paris with effect from January 28, 2015.
According to the regulations of NYSE Euronext, compartment changes are made annually on the basis of the market capitalization of the last 60 trading days of the year. Compartment B consists of listed companies with a market capitalization of between €150 million and €1 billion.
The transfer comes a few weeks after the selection of Onxeo to enter the EnterNext© PEA-PME 150, a benchmark index launched in November 2014 in response to the industry’s demand for new benchmarks.
“The transfer of our shares to Compartment B is a key event showing the progression of our market value. After a successful merger in 2014, Onxeo now relies on strong fundamentals: 3 products in an advanced clinical stage, all positioned on dynamic markets in the orphan oncology field, and on an experienced team who already registered 3 products in the US and Europe, today commercialized by our partners. The company has also strengthened its own funds with a significant capital increase in December 2014. These assets and our reinforced market visibility should increase our attractivity to international investors in the next months”, comments Nicolas Fellmann, CFO of Onxeo.